Roles for Pharmacists in the “Ending the HIV Epidemic: A Plan for America” Initiative

In 2019, President Trump announced a new initiative, Ending the HIV Epidemic: A Plan for America (EHE). EHE will use 3 key strategies—diagnose, treat, and prevent—to reduce new HIV infections at least 90% by 2030, as well as new laboratory methods and epidemiological techniques to respond quickly to potential outbreaks. Partnerships are an important component in the initiative’s success. Pharmacists and pharmacies can play important roles in EHE, including dispensing antiretroviral therapy and providing HIV screening, adherence counseling, medication therapy management, preexposure prophylaxis, and nonprescription syringe sales. The objective of this report is to discuss potential roles that pharmacists and pharmacies can play under the key strategies of EHE.

[1]  A. Jha,et al.  PrEParing to End the HIV Epidemic - California's Route as a Road Map for the United States. , 2019, The New England journal of medicine.

[2]  P. Weidle,et al.  Pharmacy Data as an Alternative Data Source for Implementation of a Data to Care Strategy. , 2019, Journal of acquired immune deficiency syndromes.

[3]  J. Myers,et al.  Pharmacists in HIV Prevention: An Untapped Potential , 2019, American journal of public health.

[4]  Eric K Farmer,et al.  The Pharmacist's Expanding Role in HIV Pre-Exposure Prophylaxis. , 2019, AIDS patient care and STDs.

[5]  Michael D. Shankle,et al.  Adherence and viral suppression among participants of the Patient-centered HIV Care Model project-a collaboration between community-based pharmacists and HIV clinical providers. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Nicol,et al.  Review of Real‐World Implementation Data on Emtricitabine‐Tenofovir Disoproxil Fumarate as HIV Pre‐exposure Prophylaxis in the United States , 2019, Pharmacotherapy.

[7]  S. Sansom,et al.  Vital Signs: HIV Transmission Along the Continuum of Care — United States, 2016 , 2019, MMWR. Morbidity and mortality weekly report.

[8]  R. Redfield,et al.  Ending the HIV Epidemic: A Plan for the United States. , 2019, JAMA.

[9]  Michael D. Shankle,et al.  Retention in HIV Care Among Participants in the Patient-Centered HIV Care Model: A Collaboration Between Community-Based Pharmacists and Primary Medical Providers. , 2019, AIDS patient care and STDs.

[10]  C. Sionean,et al.  Recent US Centers for Disease Control and Prevention Activities to Reduce HIV Stigma , 2019, Journal of the International Association of Providers of AIDS Care.

[11]  Ellsworth M. Campbell,et al.  Identifying Clusters of Recent and Rapid HIV Transmission Through Analysis of Molecular Surveillance Data , 2018, Journal of acquired immune deficiency syndromes.

[12]  P. Weidle,et al.  Factors associated with obtaining sterile syringes from pharmacies among persons who inject drugs in 20 US cities. , 2018, The International journal on drug policy.

[13]  P. Shalit,et al.  Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care. , 2018, Sexual health.

[14]  Jessica Lewis,et al.  1293. The Next Step in PrEP: Evaluating Outcomes of a Pharmacist-Run HIV Pre-Exposure Prophylaxis (PrEP) Clinic , 2018, Open Forum Infectious Diseases.

[15]  L. Yerkes,et al.  The “No Wrong Door” Approach to HIV Testing: Results From a Statewide Retail Pharmacy–Based HIV Testing Program in Virginia, 2014-2016 , 2018, Public health reports.

[16]  D. Smith,et al.  HIV Preexposure Prophylaxis, by Race and Ethnicity — United States, 2014–2016 , 2018, MMWR. Morbidity and mortality weekly report.

[17]  D. Cooper,et al.  Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. , 2018, The lancet. HIV.

[18]  O. Okoro,et al.  HIV pre-exposure prophylaxis: Exploring the potential for expanding the role of pharmacists in public health. , 2018, Journal of the American Pharmacists Association : JAPhA.

[19]  R. Gandhi.  Preexposure Prophylaxis for the Prevention of HIV , 2018 .

[20]  M. Behzadifar,et al.  Prevalence of hepatitis C virus infection among prisoners in Iran: a systematic review and meta-analysis , 2018, Harm Reduction Journal.

[21]  K. Buchacz,et al.  Notes from the Field: HIV Infection Investigation in a Rural Area — West Virginia, 2017 , 2018, MMWR. Morbidity and mortality weekly report.

[22]  M. Friend,et al.  Estimated HIV incidence and prevalence in the United States 2010–2015 , 2018 .

[23]  A. Fallin-Bennett,et al.  Pharmacists’ role in harm reduction: a survey assessment of Kentucky community pharmacists’ willingness to participate in syringe/needle exchange , 2018, Harm Reduction Journal.

[24]  H. Hagan,et al.  Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs , 2017, The Cochrane database of systematic reviews.

[25]  Jocelyn R. Wilder,et al.  The availability of pharmacies in the United States: 2007–2015 , 2017, PloS one.

[26]  M. Brandeau,et al.  Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis , 2017, PLoS medicine.

[27]  G. Duarte,et al.  Effectiveness of needle and syringe Programmes in people who inject drugs – An overview of systematic reviews , 2017, BMC Public Health.

[28]  Jennifer L. Rodis,et al.  Improving Chronic Disease Outcomes Through Medication Therapy Management in Federally Qualified Health Centers , 2017, Journal of primary care & community health.

[29]  T. Quinn,et al.  Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial , 2017, Journal of acquired immune deficiency syndromes.

[30]  J. Gallant,et al.  Antiretroviral Therapy for the Prevention of HIV-1 Transmission. , 2016, The New England journal of medicine.

[31]  Pietro Vernazza,et al.  Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. , 2016, JAMA.

[32]  Qing Zeng-Treitler,et al.  Automated alerts and reminders targeting patients: A review of the literature. , 2016, Patient education and counseling.

[33]  J. Skarbinski,et al.  Understanding Cross-Sectional Racial, Ethnic, and Gender Disparities in Antiretroviral Use and Viral Suppression Among HIV Patients in the United States , 2016, Medicine.

[34]  C. Fuller,et al.  Pharmacy Intervention to Improve HIV Testing Uptake Using a Comprehensive Health Screening Approach , 2016, Public health reports.

[35]  Michael G. Wilson,et al.  Housing Status, Medical Care, and Health Outcomes Among People Living With HIV/AIDS: A Systematic Review. , 2016, American journal of public health.

[36]  Mardge H. Cohen,et al.  IAPAC Guidelines for Optimizing the HIV Care Continuum for Adults and Adolescents , 2015, Journal of the International Association of Providers of AIDS Care.

[37]  D. Klepser,et al.  Consumer interest in community pharmacy HIV screening services. , 2015, Journal of the American Pharmacists Association : JAPhA.

[38]  M. Klepser,et al.  Pharmacist-provided rapid HIV testing in two community pharmacies. , 2015, Journal of the American Pharmacists Association : JAPhA.

[39]  P. Weidle,et al.  HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection. , 2014, Journal of the American Pharmacists Association : JAPhA.

[40]  Kholoud Porter,et al.  Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy , 2014, AIDS.

[41]  M. Hellard,et al.  Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. , 2014, International journal of epidemiology.

[42]  B. Meyerson,et al.  Pharmacists' perspectives on HIV testing in community pharmacies. , 2013, Journal of the American Pharmacists Association : JAPhA.

[43]  J. Brooks,et al.  Updates of Lifetime Costs of Care and Quality-of-Life Estimates for HIV-Infected Persons in the United States: Late Versus Early Diagnosis and Entry Into Care , 2013, Journal of acquired immune deficiency syndromes.

[44]  E. Cowan,et al.  Counselor-based rapid HIV testing in community pharmacies. , 2013, AIDS patient care and STDs.

[45]  P. Vickerman,et al.  Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  P. Saberi,et al.  Pharmacists as providers of HIV pre-exposure prophylaxis , 2012, International Journal of Clinical Pharmacy.

[47]  James D. Campbell,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[48]  S. Blaney,et al.  Pharmacy staff characteristics associated with support for pharmacy-based HIV testing. , 2012, Journal of the American Pharmacists Association : JAPhA.

[49]  T. Gilmer,et al.  Antiretroviral Therapy Adherence, Medication Use, and Health Care Costs During 3 Years of a Community Pharmacy Medication Therapy Management Program for Medi-Cal Beneficiaries with HIV/AIDS , 2011, Journal of managed care pharmacy : JMCP.

[50]  Steven C. Johnson,et al.  Assessing the effectiveness of pharmacy-based adherence interventions on antiretroviral adherence in persons with HIV. , 2011, AIDS patient care and STDs.

[51]  T. Gilmer,et al.  Medication therapy management services in community pharmacy: a pilot programme in HIV specialty pharmacies. , 2010, Journal of evaluation in clinical practice.

[52]  Sarah Lippek,et al.  A community-based approach to linking injection drug users with needed services through pharmacies: an evaluation of a pilot intervention in New York City. , 2010, AIDS education and prevention : official publication of the International Society for AIDS Education.

[53]  A. Burns.  Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). , 2008, Journal of the American Pharmacists Association : JAPhA.

[54]  Atlanta,et al.  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[55]  Carole W Cranor,et al.  The Asheville Project: long-term clinical, humanistic, and economic outcomes of a community-based medication therapy management program for asthma. , 2006, Journal of the American Pharmacists Association : JAPhA.

[56]  K. Farmer,et al.  Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study. , 2005, Clinical therapeutics.

[57]  C. Rayner,et al.  Multidisciplinary HIV adherence intervention: a randomized study. , 2004, AIDS patient care and STDs.

[58]  Mohammed Rehan Malik,et al.  Sterile syringe access conditions and variations in HIV risk among drug injectors in three cities. , 2004, Addiction.

[59]  D. Christensen,et al.  The asheville project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. , 2003, Journal of the American Pharmaceutical Association.

[60]  J. Rich,et al.  Strategies to improve access to sterile syringes for injection drug users. , 2002, The AIDS reader.

[61]  N. Schneiderman,et al.  Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men , 2000, AIDS care.